This is a routine pre-clinical milestone for a micro-cap biotech with no revenue. Monitor for the Q4 2026 CTA submission and any financing updates, as the company will likely need to raise capital to fund the study.
Price Chart
Executive Summary
Propanc Biopharma announced it is finalizing a clinical trial protocol and conducting a feasibility assessment for a First-In-Human Phase 1b study of PRP in up to 40 advanced solid tumor cancer patients. Preparatory activities are being led by Avance Clinical, with a Clinical Trial Application planned for Q4 2026. This is a pre-clinical milestone for a micro-cap biotech with no revenue, and the stock has historically declined on similar neutral announcements, warranting a low impact score.
Key Facts
- Propanc is finalizing a clinical trial protocol for a Phase 1b study of PRP in up to 40 advanced solid tumor patients.
- The feasibility assessment is being led by Avance Clinical Pty Ltd.
- A Clinical Trial Application is planned for submission in Q4 2026.
- The Phase 1b study is an open-label, dose escalation and dose expansion trial.
- The company has no revenue and a market cap of $4M.
Financial Impact
No financial data disclosed; pre-revenue biotech with $4M market cap.
Risk Factors
- No revenue or approved products; company is pre-revenue.
- Clinical trial may fail to demonstrate safety or efficacy.
- Company will likely need to raise additional capital, causing dilution.
- Historical stock performance on similar announcements has been negative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346826 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | — |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | — |
Sep 29, 2026 27d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | — |
Aug 18, 2026 9w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | — |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | — |
May 19, 2026 22w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | — |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | — |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | — |
Apr 21, 2026 26w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | — |
Mar 24, 2026 30w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers